170 related articles for article (PubMed ID: 36460279)
1. Cucurbitacin B: A review of its pharmacology, toxicity, and pharmacokinetics.
Dai S; Wang C; Zhao X; Ma C; Fu K; Liu Y; Peng C; Li Y
Pharmacol Res; 2023 Jan; 187():106587. PubMed ID: 36460279
[TBL] [Abstract][Full Text] [Related]
2. Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer.
Liu P; Xiang Y; Liu X; Zhang T; Yang R; Chen S; Xu L; Yu Q; Zhao H; Zhang L; Liu Y; Si Y
Molecules; 2019 Feb; 24(3):. PubMed ID: 30759826
[TBL] [Abstract][Full Text] [Related]
3. Cucurbitacins attenuate microglial activation and protect from neuroinflammatory injury through Nrf2/ARE activation and STAT/NF-κB inhibition.
Park SY; Kim YH; Park G
Neurosci Lett; 2015 Nov; 609():129-36. PubMed ID: 26472707
[TBL] [Abstract][Full Text] [Related]
4. Cucurbitacin B induces inhibitory effects via CIP2A/PP2A/Akt pathway in glioblastoma multiforme.
Qin S; Li J; Si Y; He Z; Zhang T; Wang D; Liu X; Guo Y; Zhang L; Li S; Li Q; Liu Y
Mol Carcinog; 2018 Jun; 57(6):687-699. PubMed ID: 29393542
[TBL] [Abstract][Full Text] [Related]
5. Cucurbitacin B reverses multidrug resistance by targeting CIP2A to reactivate protein phosphatase 2A in MCF-7/adriamycin cells.
Cai F; Zhang L; Xiao X; Duan C; Huang Q; Fan C; Li J; Liu X; Li S; Liu Y
Oncol Rep; 2016 Aug; 36(2):1180-6. PubMed ID: 27350399
[TBL] [Abstract][Full Text] [Related]
6. Potential of cucurbitacin as an anticancer drug.
Li Y; Li Y; Yao Y; Li H; Gao C; Sun C; Zhuang J
Biomed Pharmacother; 2023 Dec; 168():115707. PubMed ID: 37862969
[TBL] [Abstract][Full Text] [Related]
7. Apoptotic and antimetastatic effect of cucurbitacins in cancer: recent trends and advancement.
Kumar A; Sharma B; Sharma U; Parashar G; Parashar NC; Rani I; Ramniwas S; Kaur S; Haque S; Tuli HS
Naunyn Schmiedebergs Arch Pharmacol; 2023 Sep; 396(9):1867-1878. PubMed ID: 37010571
[TBL] [Abstract][Full Text] [Related]
8. Cucurbitacin B induces inhibitory effects via the CIP2A/PP2A/C-KIT signaling axis in t(8;21) acute myeloid leukemia.
Ma W; Xiang Y; Yang R; Zhang T; Xu J; Wu Y; Liu X; Xiang K; Zhao H; Liu Y; Si Y
J Pharmacol Sci; 2019 Apr; 139(4):304-310. PubMed ID: 30852180
[TBL] [Abstract][Full Text] [Related]
9. Cucurbitacin IIa: A review of phytochemistry and pharmacology.
Zeng Y; Wang J; Huang Q; Ren Y; Li T; Zhang X; Yao R; Sun J
Phytother Res; 2021 Aug; 35(8):4155-4170. PubMed ID: 33724593
[TBL] [Abstract][Full Text] [Related]
10. Cucurbitacins and the Immune System: Update in Research on Anti- inflammatory, Antioxidant, and Immunomodulatory Mechanisms.
Silvestre GFG; de Lucena RP; da Silva Alves H
Curr Med Chem; 2022; 29(21):3774-3789. PubMed ID: 34994307
[TBL] [Abstract][Full Text] [Related]
11. Cucurbitacin B induces autophagy and apoptosis by suppressing CIP2A/PP2A/mTORC1 signaling axis in human cisplatin resistant gastric cancer cells.
Liu X; Duan C; Ji J; Zhang T; Yuan X; Zhang Y; Ma W; Yang J; Yang L; Jiang Z; Yu H; Liu Y
Oncol Rep; 2017 Jul; 38(1):271-278. PubMed ID: 28534965
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive review on pharmacological, toxicity, and pharmacokinetic properties of phillygenin: Current landscape and future perspectives.
Wang C; Wu R; Zhang S; Gong L; Fu K; Yao C; Peng C; Li Y
Biomed Pharmacother; 2023 Oct; 166():115410. PubMed ID: 37659207
[TBL] [Abstract][Full Text] [Related]
13. Cucurbitacins: A Systematic Review of the Phytochemistry and Anticancer Activity.
Cai Y; Fang X; He C; Li P; Xiao F; Wang Y; Chen M
Am J Chin Med; 2015; 43(7):1331-50. PubMed ID: 26503558
[TBL] [Abstract][Full Text] [Related]
14. Cucurbitacin E glucoside alleviates concanavalin A-induced hepatitis through enhancing SIRT1/Nrf2/HO-1 and inhibiting NF-ĸB/NLRP3 signaling pathways.
Mohamed GA; Ibrahim SRM; El-Agamy DS; Elsaed WM; Sirwi A; Asfour HZ; Koshak AE; Elhady SS
J Ethnopharmacol; 2022 Jun; 292():115223. PubMed ID: 35354089
[TBL] [Abstract][Full Text] [Related]
15. Treatment with cucurbitacin B alone and in combination with gefitinib induces cell cycle inhibition and apoptosis via EGFR and JAK/STAT pathway in human colorectal cancer cell lines.
Yar Saglam AS; Alp E; Elmazoglu Z; Menevse S
Hum Exp Toxicol; 2016 May; 35(5):526-43. PubMed ID: 26183715
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous determination of cucurbitacin B and cucurbitacin E in rat plasma by UHPLC-MS/MS: A pharmacokinetics study after oral administration of cucurbitacin tablets.
Wang Z; Zhu W; Gao M; Wu C; Yang C; Yang J; Wu G; Yang B; Kuang H
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Oct; 1065-1066():63-69. PubMed ID: 28946127
[TBL] [Abstract][Full Text] [Related]
17. Cucurbitacin B controls M2 macrophage polarization to suppresses metastasis via targeting JAK-2/STAT3 signalling pathway in colorectal cancer.
Zhang H; Zhao B; Wei H; Zeng H; Sheng D; Zhang Y
J Ethnopharmacol; 2022 Apr; 287():114915. PubMed ID: 34954267
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological properties of indirubin and its derivatives.
Yang L; Li X; Huang W; Rao X; Lai Y
Biomed Pharmacother; 2022 Jul; 151():113112. PubMed ID: 35598366
[TBL] [Abstract][Full Text] [Related]
19. Cucurbitacin B exerts anti-cancer activities in human multiple myeloma cells in vitro and in vivo by modulating multiple cellular pathways.
Yang T; Liu J; Yang M; Huang N; Zhong Y; Zeng T; Wei R; Wu Z; Xiao C; Cao X; Li M; Li L; Han B; Yu X; Li H; Zou Q
Oncotarget; 2017 Jan; 8(4):5800-5813. PubMed ID: 27418139
[TBL] [Abstract][Full Text] [Related]
20. Biological activities and potential molecular targets of cucurbitacins: a focus on cancer.
Chen X; Bao J; Guo J; Ding Q; Lu J; Huang M; Wang Y
Anticancer Drugs; 2012 Sep; 23(8):777-87. PubMed ID: 22561419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
